Navigation Links
Lorus initiates development program exploring novel route of administration for LOR-2040
Date:4/22/2008

TORONTO, April 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ('Lorus'), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the start of a development program aimed at expanding the therapeutic application of its lead clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer.

The new development program will examine direct (intravesical) administration of LOR-2040 into the bladder as a treatment for superficial or non-invasive bladder cancer. Formal toxicology evaluation, which is currently in progress, will be used to determine the appropriate human dose and dose schedule for LOR-2040 with this route of administration.

Results of these studies will be used in support of an Investigational New Drug (IND) application for the use of LOR-2040 in the treatment of bladder cancer. Lorus intends to submit the IND during Q3, 2008, following successful completion of the toxicology program.

LOR-2040, formerly known as GTI-2040, has shown potent antiproliferative activity and target downregulation in bladder cancer in preclinical studies. LOR-2040 is currently being investigated in several phase I and phase II clinical trials in a broad range of cancer indications, both alone and in combination with a number of standard cancer therapies. In clinical trials, LOR-2040 has demonstrated a high safety profile when administered intravenously, which is the current route of administration for this drug.

In the U.S. more than 60,000 new cases of bladder cancer are diagnosed each year, which accounts for approximately 13,000 deaths annually. At initial diagnosis, up to 90% of subjects with bladder cancers have superficial disease that is confined to the inner layers of tissue in the urinary bladder. Systemic chemotherapy is considered less effective than the intravesical (instilled in the bladder) agents in treating lo
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
4. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
5. SemBioSys initiates toxicology study for safflower-produced insulin
6. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
7. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
10. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
11. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... AMSTERDAM, February 20 Elsevier announced today,that ... abstract and,citation (A&C) database, was chosen by ... in Research for Australia (ERA) initiative. , ... will assess research quality within Australia,s higher,education ...
... of the world,s most versatile and widely used chemicals. ... is commonly used as a bleach, an antiseptic and ... J. Kiely, hydrogen peroxide has eluded the best efforts ... environmentally friendly means of producing it. , "Hydrogen peroxide ...
... Safety Study in Patients with Severe Post-Operative Pain; ... and Support NDA SubmissionSYDNEY and BEDMINSTER, N.J., Feb. ... QRXPY), a clinical-stage specialty pharmaceutical company focused on ... and central nervous system (CNS) disorders, announced today ...
Cached Biology Technology:The Australian Research Council Selects Scopus for the Evaluation of the Australian Research Landscape 2The Australian Research Council Selects Scopus for the Evaluation of the Australian Research Landscape 3Gold-palladium nanoparticles achieve greener, smarter production of hydrogen peroxide 2Gold-palladium nanoparticles achieve greener, smarter production of hydrogen peroxide 3Gold-palladium nanoparticles achieve greener, smarter production of hydrogen peroxide 4QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy 2QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy 3QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy 4
(Date:4/15/2014)... 2014, Irvine, Calif. UC Irvine neurobiologists have found ... when transplanted into the brains of mice with the ... is published in the journal Stem Cells Research ... to work in two different mouse models. , ... dementia, is associated with accumulation of the protein amyloid-beta ...
(Date:4/15/2014)... know as early as 2020 how high sea levels ... team of researchers including Florida International University scientist Rene ... Science Foundation,s (NSF) Florida Coastal Everglades Long-Term Ecological Research ... in ecosystems from coral reefs to deserts, mountains to ... sea level rise is one of the most certain ...
(Date:4/15/2014)... UC San Diego have succeeded in visualizing the ... for growth and resistance to drought. The achievement ... determine how the hormone helps plants respond to ... continuing increase in the atmosphere,s carbon dioxide, or ... in the April 15 issue of the scientific ...
Breaking Biology News(10 mins):UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Long-term predictions for Miami sea level rise could be available relatively soon 2Biologists develop nanosensors to visualize movements and distribution of plant hormone 2
... earths system of mid-ocean ridges plays a pivotal role in ... heat flow from the interior, and the chemistry of rock, ... that scientists discovered the existence of vast plumbing systems under ... spit it back out from seafloor ventsa process that brings ...
... of the most common human parasites, Toxoplasma gondii, uses a ... increase its numbers and when to remain dormant, researchers at ... The scientists report this week in Nature that they ... (ABA), with a plant herbicide. Low doses of the herbicide ...
... Association of Water Companies (NAWC) held its annual ... Bob Iacullo presented the 2007 Management Innovation Awards. ... to share innovative approaches to issues relevant to ... to United Water for the entry Senior Design ...
Cached Biology News:Quakes under Pacific floor reveal unexpected circulatory system 2Quakes under Pacific floor reveal unexpected circulatory system 3Disrupting common parasites' ability to 'talk' to each other reduces infection 2Disrupting common parasites' ability to 'talk' to each other reduces infection 3United Water, in partnership with Stevens, wins Management Innovation Award 2
... (eIF4E-binding protein II) is involved in translation ... kidney. PHAS proteins bind to eIF-4E, the ... capped mRNA in vitro and in cells. ... of PHAS/eIF-4E complexes. This allows eIF-4E to ...
... 2 (VMAT2). An antibody made to the ... at ~55 kDa in postnuclear supernatants of ... wild type cells (2). Some additional bands, ... also detected and remain unaffected by the ...
... Anti-Matrix Metalloproteinase-2, Hinge Region By immunoblotting ... native protein. It reacts with free MMP-2 ... antibody buffered aqueous glycerol solution ... pH 7.4, containing 50% glycerol and 15 ...
Acetylcholinesterase from human and monkey....
Biology Products: